Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 2,748 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: High Activity Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effectiveness of a Multi-Level Smoking Cessation Program for High-Risk Women in Rural Communities

NCT04340531
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Best Practice, Survey Administration, Tobacco Cessation Counseling, Training
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 64 Years
Enrollment
810 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
4
States / cities
Lexington, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 30, 2026, 10:58 PM EDT
Recruiting Not applicable Interventional

Cortical Priming to Optimize Gait Rehabilitation in Stroke: a Renewal

NCT04477330
View directory record Official record
Conditions
Stroke
Interventions
Transcranial direct current stimulation (tDCS), Ankle motor training, High intensity interval speed based treadmill training (HIISTT)
Other · Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 30, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study

NCT00067600
View directory record Official record
Conditions
Osteoporosis
Interventions
Diet with increased fruits, vegetables, and calcium, Increased high impact activity and resistance training
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
14 Years to 16 Years · Female only
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 30, 2026, 10:58 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536
View directory record Official record
Conditions
Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
Nemtabrutinib
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 30, 2026, 10:58 PM EDT
Completed Not applicable Interventional

StressLess Yoga Study

NCT06260098
View directory record Official record
Conditions
Stress
Interventions
Yoga with High Breath work & meditation; Low movement/postures, Yoga with Low Breath work & meditation; High movement/postures
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 30, 2026, 10:58 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mechanistic Validation of Human Multipolar TES-TI: Amplitude Modulation, Frequency, and Benchmarking

NCT07752745
View directory record Official record
Conditions
Transcranial Electric Stimulation
Interventions
TES-TI with hdEEG
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 10:58 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Preventing Obesity in Military Communities-Adolescents

NCT02671292
View directory record Official record
Conditions
Obesity, Overweight, Binge Eating
Interventions
Interpersonal Psychotherapy, Health Education
Behavioral · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
12 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland • Fort Belvoir, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 30, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors

NCT02423057
View directory record Official record
Conditions
Neoplasms, Solid Tumors
Interventions
TdCyd
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

NCT03103412
View directory record Official record
Conditions
Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
Interventions
TD-3504, 15N2-tofacitinib, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 30, 2026, 10:58 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Vitamin D and Physical Activity on Bone Health

NCT01419730
View directory record Official record
Conditions
Bone Metabolism Biomarkers, Bone Mineral Density, Physical Fitness
Interventions
Vitamin D3, Physical Activity
Drug · Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 30, 2026, 10:58 PM EDT
Recruiting Not applicable Interventional

Intermittent Theta Burst Stimulation (iTBS) for Emotion Regulation in Bipolar Disorder

NCT06274567
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Transcranial Magnetic Stimulation (TMS), Sham (placebo) TMS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
24 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Charlestown, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 30, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

NCT02816736
View directory record Official record
Conditions
Heart Failure
Interventions
LCZ696, valsartan, LCZ696 placebo, valsartan placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Beverly Hills, California • Sacramento, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 30, 2026, 10:58 PM EDT
Not yet recruiting Not applicable Interventional

Implementing Stepped Financial and Legal Navigation to Mitigate Financial Toxicity in Adolescent and Young Adult Cancer Patients Oncology Financial and Legal Navigation (OFLN)

NCT07849699
View directory record Official record
Conditions
Financial Toxicity, Cancer, Adolescent, Young Adult Cancer Survivors
Interventions
Oncology Financial and Legal Navigation (OFLN) Stepped: Low Intensity, Oncology Financial and Legal Navigation (OFLN) Standard, Oncology Financial and Legal Navigation (OFLN) Stepped: High-Intensity
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 39 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 30, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis

NCT02547922
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Anifrolumab, Placebo
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
17
States / cities
Glendale, Arizona • Phoenix, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 30, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

NCT03538301
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ND-L02-s0201 (Low Dose), ND-L02-s0201 (High Dose), Other: Placebo
Drug · Other
Lead sponsor
Nitto Denko Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Tucson, Arizona • Los Angeles, California • Northridge, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 30, 2026, 10:58 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

NCT03955471
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Scottsdale, Arizona • Duarte, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 30, 2026, 10:58 PM EDT
Recruiting Not applicable Interventional

CARS: Cannabis and Alcohol Reduction Study

NCT05486234
View directory record Official record
Conditions
Cannabis Use, Alcohol Use, Unspecified, Substance Use, Substance Use Disorders
Interventions
modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias, modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years to 17 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 10:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Food, Adolescence, Mood, and Exercise

NCT02015377
View directory record Official record
Conditions
Overweight, Obesity
Interventions
High sugar versus low sugar meals
Other
Lead sponsor
University of Southern California
Other
Eligibility
14 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 30, 2026, 10:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

DNA Methylation and Cancer Prevention: Duration and Intensity of Exercise

NCT02032628
View directory record Official record
Conditions
DNA Methylation
Interventions
Exercise
Behavioral
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
30 Years to 45 Years · Female only
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 30, 2026, 10:58 PM EDT
Completed Not applicable Interventional

Peer-Administered Asthma Self-Management Intervention in Urban Middle Schools

NCT03446365
View directory record Official record
Conditions
Asthma
Interventions
ASMAS, Asthma education plus child health
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
11 Years to 14 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 30, 2026, 10:58 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis

NCT00074698
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
FG-3019
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
21 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
Denver, Colorado • Ann Arbor, Michigan • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 30, 2026, 10:58 PM EDT
Active, not recruiting No phase listed Observational

Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys

NCT05714514
View directory record Official record
Conditions
Kidney Transplantation in Highly Sensitized Patients
Interventions
Imlifidase administered in the ConfIdeS study, Best available treatment administered in the ConfIdeS study
Drug · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 30, 2026, 10:58 PM EDT
Completed Not applicable Interventional

Effects of a Short-term Exercise Intervention on Sleep in Women Exposed to Trauma: A Randomized Controlled Trial

NCT05097352
View directory record Official record
Conditions
Traumatic Stress Disorder, Post Traumatic Stress Disorder, Trauma and Stressor Related Disorders, Mental Disorders, Exercise
Interventions
High Intensity Interval Training (HIIT), Waitlist
Behavioral · Other
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 30, 2026, 10:58 PM EDT